8 studies found for:    optinose
Show Display Options
Download search resultsDownload the search results for:
optinose (8 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
Condition: Migraine
Intervention: Drug: Sumatriptan
2 Active, not recruiting Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without
Conditions: Migraine;   Headaches
Interventions: Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally;   Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
3 Recruiting Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Condition: Healthy Male Adults
Interventions: Drug: 8IU intranasal oxytocin;   Drug: 24 IU intranasal oxytocin;   Drug: 1 IU intravenous oxytocin;   Drug: Placebo
4 Completed Safety and Efficacy Study of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
Condition: Migraine Headache
Interventions: Drug: Sumatriptan;   Drug: Placebo
5 Recruiting Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Condition: Bilateral Nasal Polyposis
Intervention: Drug: fluticasone propionate
6 Recruiting Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
Condition: Chronic Sinusitis With or Without Nasal Polyps
Intervention: Drug: Fluticasone Propionate
7 Recruiting Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps
Condition: Chronic Sinusitis With or Without Nasal Polyps
Intervention: Drug: Fluticasone Propionate
8 Recruiting Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
Condition: Bilateral Nasal Polyposis
Intervention: Drug: fluticasone propionate

Indicates status has not been verified in more than two years